Comparison of the percentage of SLE/RA patients on immunosuppressants that were taking HCQ, for COVID-19 diagnosis versus other infections or outpatient visits, finding a similar percentage in each case.
No mortality of severity information is provided to determine if HCQ treated patients fared better. No adjustment for concomitant medications or severity.
risk of case, 9.0% higher, RR 1.09, p = 0.62, treatment 55 of 10,700 (0.5%), control 104 of 22,058 (0.5%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in the after exclusion results of meta
not fully adjusting for the baseline risk differences within systemic autoimmune patients.
Singer et al., 8/5/2020, retrospective, database analysis, USA, North America, preprint, 3 authors.